Is Portal Inflow Modulation Always Necessary for Successful Utilization of Small Volume Living Donor Liver Grafts?
Sanjay Goja, Manish Srivastava, Manoj Singh, Rajeev Sinha, Rahul Roy, Varun Mahabaleshwar, Pankaj Sonar – 28 October 2019
Correction
28 October 2019
Frailty Is Associated With Increased Rates of Acute Cellular Rejection Within 3 Months After Liver Transplantation
Laila Fozouni, Yara Mohamad, Adrienne Lebsack, Chris Freise, Peter Stock, Jennifer C. Lai – 26 October 2019 – Frailty, a state of decreased physiological reserve, has been associated with dysregulation of the immune system. We hypothesized that frailty is associated with differential rates of acute cellular rejection (ACR) in liver transplantation (LT) recipients. Our study included LT recipients from 2014 to 2016 who had a pre‐LT frailty assessment using the liver frailty index (LFI). Frailty was defined as an LFI ≥4.5.
Letter to the Editor: Glomerular Filtration Rate Assessment in Liver Disease (GRAIL): Are We There Yet?
Joana Carvão, Luís Jasmins – 26 October 2019
RNA Interference Therapy With ARC‐520 Results in Prolonged Hepatitis B Surface Antigen Response in Patients With Chronic Hepatitis B Infection
Man‐Fung Yuen, Ingolf Schiefke, Jung‐Hwan Yoon, Sang Hoon Ahn, Jeong Heo, Ju Hyun Kim, Henry Lik Yuen Chan, Ki Tae Yoon, Hartwig Klinker, Michael Manns, Joerg Petersen, Thomas Schluep, James Hamilton, Bruce D. Given, Carlo Ferrari, Ching‐Lung Lai, Stephen A. Locarnini, Robert G. Gish – 26 October 2019
Reply:
Grace Lai‐Hung Wong, Vincent Wai‐Sun Wong – 26 October 2019
Reply:
Sumeet K. Asrani – 25 October 2019
LiverLearning®: 2019 Webinar: Integrated Management of Alcohol-Related Liver Disease with Hepatologists and Addiction Specialists
Patients with ALD and alcohol-related acute hepatitis (AH) have two diseases of liver failure with complications and of alcoholism or alcohol use disorder (AUD). Clearly, these patients need at least two or may be more specialists as basis for integrated and effective management and improved outcomes of this disorder. We will utilize a live webinar format that will be recorded for on-demand viewing on Liver Learning ® .Ashwani K. Singal Ashwani K.
Short‐Duration Pan‐Genotypic Therapy With Glecaprevir/Pibrentasvir for 6 Weeks Among People With Recent Hepatitis C Viral Infection
Marianne Martinello, Chloe Orkin, Graham Cooke, Sanjay Bhagani, Edward Gane, Ranjababu Kulasegaram, David Shaw, Elise Tu, Kathy Petoumenos, Philippa Marks, Jason Grebely, Gregory J. Dore, Mark Nelson, Gail V. Matthews – 24 October 2019